CVS Caremark Formulary Update 2026: How the New GLP-1 Coverage Cuts Your Copay (and How to Appeal if It Doesn’t)
CVS Caremark’s May 2026 bulletin puts Zepbound back on the map and reorganizes every GLP-1 into tighter tiers with step-therapy and prior-auth hoops. Learn exactly what changed, what you’ll now pay for Ozempic, Wegovy, Mounjaro and more, and how to win a coverage appeal in one phone call.
CVS Caremark’s May 28, 2026 formulary update announced that Zepbound will re-enter the national commercial formularies as a preferred GLP-1 effective October 1 - and, at the same time, shifted Ozempic, Wegovy, Mounjaro and every other GLP-1 into stricter tiers that require step therapy, prior authorization and quantity limits. Members whose claims are denied can still lock in the lowest copay by completing a one-page appeal and submitting the right clinical notes.
- CVS Caremark confirmed on May 28 that Zepbound will be reinstated as a preferred brand on its Standard, Value and Advanced Control formularies effective October 1, 2026. (investing.com)
- All injectable GLP-1s (Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, Zepbound) now carry Step Therapy, Prior Authorization and Quantity Limits tags on the Value Formulary. (caremark.com)
- Most employer plans using CVS Caremark charge $0 for Tier 1 generics, $20 for Tier 2 preferred brands and $25 for Tier 3 non-preferred brands for diabetes drugs. (caremark.com)
- CVS projects a 15 % drop in net GLP-1 cost per prescription in 2026 and caps member cost-share in its optional weight-management copay tier at $200 per month. (business.caremark.com)
- You can appeal a denial by faxing CVS Caremark’s one-page “GLP-1 Weight Loss Exception” form with BMI, comorbidity and 6-month lifestyle documentation from your doctor.
May 2026 Update: Zepbound Returns and All GLP-1s Move Into Stricter Tiers
CVS Caremark’s press release on May 28, 2026 said the company would restore Zepbound as a preferred option on its commercial formularies after renegotiating price concessions with Eli Lilly. Coverage takes effect on October 1, 2026 for employers that adopt the template formulary. (cvshealth.com)
Why the reversal? CVS Caremark dropped Zepbound in mid-2025 when Wegovy undercut Lilly’s net price. Re-adding Zepbound gives plan sponsors leverage to hold both manufacturers to aggressive rebate guarantees, which CVS says will lower average GLP-1 net cost by about 15 % this year. (business.caremark.com)
How the New Tiers, Step Therapy and Prior-Auth Rules Work
The Value Formulary PDF dated October 1, 2026 lists every GLP-1 as “ST; PA**; QL,” meaning you must first try a lower-net-cost agent, obtain prior authorization and stay within quantity limits.
| Drug | Formulary Tier | Utilization Flags | Notes |
|---|---|---|---|
| Zepbound | Tier 2 (Preferred Brand) | ST, PA**, QL | Back on formulary Oct 1 2026. Must fail Wegovy or demonstrate medical need. (caremark.com) |
| Wegovy | Tier 2 | ST, PA**, QL | First-line preferred for weight management. (caremark.com) |
| Ozempic | Tier 2 | ST, PA**, QL | Labeled for diabetes; weight-loss use requires additional documentation. (caremark.com) |
| Mounjaro | Tier 2 | ST, PA**, QL | Tirzepatide for diabetes; must meet HbA1c criteria or fail metformin. (caremark.com) |
| Rybelsus | Tier 2 | ST, PA**, QL | Oral semaglutide-often preferred before injectables. |
| Trulicity | Tier 3 (Non-Pref. Brand) | PA**, QL | Higher copay unless clinical reason to avoid preferred products. (caremark.com) |
Step therapy in plain English: CVS Caremark will deny claims for Tier 2 drugs unless the patient has tried and failed the designated first-step agent (often generic metformin for diabetes or lifestyle program for weight loss) or the prescriber shows it is medically inappropriate.
What the Changes Mean for Your Monthly Copay
Copay amounts still vary by employer, but many commercial plans using CVS Caremark follow the template below for 30-day supplies of preferred diabetes agents:
| Tier | Examples | Typical 30-day Copay |
|---|---|---|
| Tier 1 (Generic) | Metformin, Glipizide | $0 |
| Tier 2 (Preferred Brand) | Zepbound, Ozempic, Wegovy, Mounjaro | $20 |
| Tier 3 (Non-Preferred Brand) | Trulicity, Saxenda | $25 |
| Weight-Management Copay Tier (Optional) | Zepbound or Wegovy for BMI ≥ 30 | Capped at $200 |
The $0 / $20 / $25 structure comes from CVS Caremark’s April 2026 diabetes list for the State of Minnesota plan. (caremark.com) Plans that adopt the weight-management tier cap member cost-share at $200 per month. (business.caremark.com)
Good to know: Even if your employer chooses a higher differential, the May 2026 rebate renegotiations lowered the net price of injectable GLP-1s by ~15 %, which usually translates into a lower coinsurance bill if your plan uses percentage cost-share.
Want an instant GLP-1 price check?
Search any pharmacy in seconds and see if cash pricing beats your new copay.
Step-by-Step: How to Appeal a CVS Caremark GLP-1 Denial
Caught by a denial? Appeals succeed when the letter matches CVS Caremark’s published criteria-BMI proof, 6-month lifestyle program notes and comorbidities. Here’s the fastest route:
1. Download the right form. CVS Caremark’s “Zepbound Weight Loss PA” (form 6192-C) or the matching Ozempic / Wegovy forms are on Caremark.com. (info.caremark.com)
2. Fill in the easy parts yourself. Add member ID, group number and drug name before handing it to your prescriber.
3. Ask your prescriber to attach:
- BMI ≥ 30 kg/m² (or ≥ 27 with hypertension, T2D or dyslipidemia)
- 6-month documented lifestyle program (visit notes, dietitian letters, etc.)
- Previous drug trial history (metformin, phentermine or first-step GLP-1)
- Statement that other GLP-1s are contraindicated or ineffective
4. Fax to the dedicated PA line: 1-888-836-0730. Keep the confirmation page.
5. Call within 24 hours. Members can call 1-800-294-5979, quote the reference number and ask for “expedited review for continuity of care.” Be polite but firm:
“Hi, my doctor faxed a PA for Zepbound yesterday. My BMI is 36 with hypertension. I’ve completed six months of supervised diet. Can you confirm receipt and expedite because I need to avoid an interruption in therapy?”
6. Escalate if denied again. Request a peer-to-peer review. Your prescriber can speak directly with a CVS Caremark clinical pharmacist to clarify any missing criteria.
Should you file an appeal or pay cash?
Check the column that fits your situation:
✅ Appeal Makes Sense
- Your BMI and comorbidity meet CVS Caremark criteria
- You can get a doctor’s note within a week
- Your plan’s Tier 2 copay is under $200
🏥 Pay Cash or Compare Prices
- You do not meet BMI/comorbidity thresholds
- Employer has fully excluded weight-loss GLP-1s
- Time-sensitive need (e.g., surgery clearance) and appeal could take weeks
Other Ways to Keep Your GLP-1 Cost Down
Use Rx.com’s comparison tool. Many members find that a free Rx discount card prices Ozempic or Mounjaro below their plan copay, especially during the deductible phase.
Break your script into two 0.75 mg Wegovy pens. Our prior-auth guide explains how splitting doses can trim 15-20 % off monthly spend.
Run the math first. The 12-month GLP-1 cost calculator shows employer copay vs. discount-card scenarios side by side.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain - could signal pancreatitis, a known GLP-1 risk
- Persistent nausea or vomiting lasting more than two days
- Signs of thyroid tumor - neck mass, hoarseness, difficulty swallowing
- Signs of gallbladder disease - fever with right-upper-quadrant pain
- Vision changes in patients with diabetic retinopathy
- Allergic reaction - rash, swelling of face or throat, difficulty breathing
- Thoughts of self-harm; call or text 988 if you feel unsafe
Scientific References
- CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight-management medications with expanded coverage options. Press release, May 28 2026.
- Reuters. CVS brings back coverage for Lilly’s obesity drug Zepbound. May 28 2026.
- CVS Caremark. Value Formulary, effective October 1 2026.
- CVS Caremark. State of Minnesota Diabetes Drug List. April 2026.
- CVS Caremark. 2026 GLP-1 Outlook: A strategic roadmap to manage spend and trend. 2026.
- CVS Caremark. Zepbound Prior Authorization Criteria (Ref 6192-C). 2025.
- pubmed.ncbi.nlm.nih.gov/31767182
Frequently Asked Questions
Does the CVS Caremark update affect Medicare plans?
No. The May 2026 bulletin applies only to commercial employer-sponsored plans. Medicare Part D formularies follow separate CMS-approved updates published each fall.
Will every employer automatically cover Zepbound again?
Not necessarily. Employers choose whether to adopt CVS Caremark’s template formulary. Ask your HR or benefits portal if they will implement the October 1 update.
How long does a CVS Caremark prior authorization decision take?
The pharmacy benefit manager aims for a 2-business-day turnaround once all documents are received. Incomplete forms reset the clock, so send everything at once.
Can I bypass step therapy if I already used another GLP-1?
Yes. Provide pharmacy claims or medical records showing prior use and inadequate response; CVS Caremark counts that as a failed step.
Is Foundayo (oral tirzepatide) covered?
Foundayo cleared CVS Caremark’s new-to-market block on June 1 2026 but remains non-preferred with step therapy and prior authorization requirements.
Does CVS mail order offer lower copays for GLP-1s?
For many plans, a 90-day supply through CVS Mail Pharmacy costs two times the 30-day copay, effectively shaving 33 % off monthly out-of-pocket costs.
What if my plan excludes all anti-obesity drugs?
If your employer has an explicit exclusion, appeals are rarely successful. Compare cash prices with an Rx.com discount card or discuss compounded alternatives with your physician.
Connect With a Weight-Loss Provider Today
Need a doctor who understands CVS Caremark’s new rules and can complete the paperwork fast? Start an online visit in minutes and get personalized GLP-1 care.
